Core Insights - As of August 12, 2025, the stock price of Jinbo Bio reported at 302.98 yuan, down by 17.05 yuan, a decrease of 5.33% from the previous trading day [1] - Jinbo Bio is a national-level specialized and innovative "little giant" enterprise focusing on the research and industrialization of recombinant humanized collagen and anti-HPV biological protein technology [1] - The company's products are widely used in various medical fields, particularly in dermatology, gynecology, and surgery, with strong market competitiveness in medical anti-aging and aesthetic medicine [1] Financial Performance - In the first half of 2025, Jinbo Bio achieved operating revenue of 859 million yuan, representing a year-on-year growth of 42.43% [1] - The net profit attributable to the parent company reached 392 million yuan, with a year-on-year increase of 26.65% [1] - Notably, the company's R&D investment significantly increased, with R&D expenses amounting to 45.8 million yuan, a year-on-year growth of 85.43%, and R&D expenses accounted for 5.33% of operating revenue [1]
锦波生物股价回落5.33% 上半年研发费用同比大增85%